KCNK2 and atrial fibrillation: From a pathophysiological point of view, sensitization of TREK-1 by LecA might be a starting point for novel therapeutic targeting of atrial fibrillation or heart failure – two pathologies where TREK-1 has been reported to be suppressed (Lugenbiel et al., 2017).